WO2004020633A1 - ヒト抗ヒトインターロイキン−6抗体及び該抗体フラグメント - Google Patents
ヒト抗ヒトインターロイキン−6抗体及び該抗体フラグメント Download PDFInfo
- Publication number
- WO2004020633A1 WO2004020633A1 PCT/JP2003/010923 JP0310923W WO2004020633A1 WO 2004020633 A1 WO2004020633 A1 WO 2004020633A1 JP 0310923 W JP0310923 W JP 0310923W WO 2004020633 A1 WO2004020633 A1 WO 2004020633A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human
- antibody
- chain
- gene fragment
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03791369A EP1536012A4 (en) | 2002-08-30 | 2003-08-28 | HUMAN-TYPE ANTIHUMAN INTERLEUKIN-6 ANTIBODY ANTIBODY ANTIBODY FRAGMENT |
CN038203340A CN1678744B (zh) | 2002-08-30 | 2003-08-28 | 人的抗人白细胞介素-6抗体以及所述抗体的片段 |
JP2004532751A JP4463104B2 (ja) | 2002-08-30 | 2003-08-28 | ヒト抗ヒトインターロイキン−6抗体及び該抗体フラグメント |
CA002496523A CA2496523A1 (en) | 2002-08-30 | 2003-08-28 | Human antihuman interleukin-6 antibody and fragment of the antibody |
AU2003261787A AU2003261787B2 (en) | 2002-08-30 | 2003-08-28 | Human antihuman interleukin-6 antibody and fragment of the antibody |
US10/526,072 US7482436B2 (en) | 2002-08-30 | 2003-08-28 | Human antihuman interleukin-6 antibody and fragment of antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-253036 | 2002-08-30 | ||
JP2002253036 | 2002-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004020633A1 true WO2004020633A1 (ja) | 2004-03-11 |
Family
ID=31972776
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/010923 WO2004020633A1 (ja) | 2002-08-30 | 2003-08-28 | ヒト抗ヒトインターロイキン−6抗体及び該抗体フラグメント |
Country Status (8)
Country | Link |
---|---|
US (1) | US7482436B2 (ja) |
EP (1) | EP1536012A4 (ja) |
JP (1) | JP4463104B2 (ja) |
KR (1) | KR20050058486A (ja) |
CN (1) | CN1678744B (ja) |
AU (1) | AU2003261787B2 (ja) |
CA (1) | CA2496523A1 (ja) |
WO (1) | WO2004020633A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009518023A (ja) * | 2005-12-09 | 2009-05-07 | ユセベ ファルマ ソシエテ アノニム | ヒトil−6に対して特異性を有する抗体分子 |
JP2009545319A (ja) * | 2006-08-03 | 2009-12-24 | バクシネックス,インコーポレーテッド | 抗il−6モノクローナル抗体およびその使用 |
JP2011201888A (ja) * | 2005-04-29 | 2011-10-13 | Centocor Inc | 抗−il−6抗体、組成物、方法および使用 |
US8153128B2 (en) | 2006-11-30 | 2012-04-10 | Medimmune Limited | Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor |
JP2012508762A (ja) * | 2008-11-13 | 2012-04-12 | フェムタ ファーマシューティカルズ インコーポレイテッド | ヒト化抗il−6抗体 |
US8198414B2 (en) | 2006-11-30 | 2012-06-12 | Medimmune Limited | Anti-human IL-6 antibodies |
WO2020223565A1 (en) | 2019-05-01 | 2020-11-05 | Corvidia Therapeutics, Inc. | Anti-il-6 antibody formulation |
US11203636B2 (en) | 2017-02-01 | 2021-12-21 | Yale University | Treatment of existing left ventricular heart failure |
US11384143B2 (en) | 2018-01-05 | 2022-07-12 | Novo Nordisk A/S | Methods for treating IL-6 mediated inflammation without immunosuppression |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS52643B (en) * | 2006-06-02 | 2013-06-28 | Regeneron Pharmaceuticals Inc. | HIGH AFINITY ANTIBODIES TO THE HUMAN IL-6 RECEPTOR |
US8414897B1 (en) | 2006-10-02 | 2013-04-09 | The Uab Research Foundation | Pathway for Th-17 cell development and methods utilizing same |
US8178101B2 (en) * | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
HUE043782T2 (hu) | 2007-05-21 | 2019-09-30 | Alderbio Holdings Llc | IL-6 elleni antitestek és alkalmazásuk |
EP2162469A4 (en) * | 2007-05-21 | 2012-08-01 | Alderbio Holdings Llc | NEW METHODS OF HUMANIZING RABBIT ANTIBODIES AND HUMANIZED RABBIT ANTIBODIES |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
CN101796197B (zh) | 2007-06-08 | 2014-02-12 | 比奥根艾迪克Ma公司 | 预测抗tnf响应性或无响应性的生物标志物 |
US20100203009A1 (en) * | 2007-10-02 | 2010-08-12 | The Uab Research Foundation | Pathway for Th-17 Cell Development and Methods Utilizing Same |
EP2297202B1 (en) | 2008-05-13 | 2016-01-13 | NovImmune SA | Anti-il-6/il-6r antibodies and methods of use thereof |
US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
US9452227B2 (en) * | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
MX2011005408A (es) | 2008-11-25 | 2011-06-16 | Alder Biopharmaceuticals Inc | Antagonistas de il-6 para prevenir o tratar la trombosis. |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
WO2011066374A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
ES2847891T3 (es) | 2010-11-23 | 2021-08-04 | Vitaeris Inc | Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral |
MX342810B (es) * | 2011-03-03 | 2016-10-13 | Apexigen Inc | Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso. |
ES2662020T3 (es) * | 2012-10-22 | 2018-04-05 | Fountain Biopharma Inc. | Anticuerpos contra la interleucina-6 y sus usos |
MX2018000778A (es) | 2015-07-31 | 2018-08-15 | Medimmune Ltd | Metodos para tratar trastornos mediados por hepcidinas. |
CN110283249A (zh) * | 2018-03-19 | 2019-09-27 | 江苏莱博德医疗科技有限公司 | 一种抗白介素6的人ScFv单链抗体 |
CN113365663A (zh) | 2018-08-30 | 2021-09-07 | Hcw生物科技公司 | 单链嵌合多肽和其用途 |
US11672826B2 (en) | 2018-08-30 | 2023-06-13 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
WO2020047299A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
CN114269903A (zh) | 2019-06-21 | 2022-04-01 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
JP2023519106A (ja) | 2020-02-11 | 2023-05-10 | エイチシーダブリュー バイオロジックス インコーポレイテッド | クロマトグラフィー樹脂およびその使用 |
CA3169231A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of treating age-related and inflammatory diseases |
CN115380045A (zh) | 2020-02-11 | 2022-11-22 | Hcw生物科技公司 | 激活调节性t细胞的方法 |
CA3181417A1 (en) | 2020-04-29 | 2021-11-04 | HCW Biologics, Inc. | Anti-cd26 proteins and uses thereof |
CA3184756A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
WO2023168363A1 (en) | 2022-03-02 | 2023-09-07 | HCW Biologics, Inc. | Method of treating pancreatic cancer |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5959085A (en) * | 1993-11-23 | 1999-09-28 | Schering Corporation | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
EP1074268B1 (en) * | 1998-03-17 | 2008-01-16 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for inflammatory intestinal diseases containing il-6 receptor antagonist antibodies |
CA2564432A1 (en) | 2004-04-27 | 2005-11-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human anti-amyloid .beta. peptide antibody and fragment of said antibody |
-
2003
- 2003-08-28 CN CN038203340A patent/CN1678744B/zh not_active Expired - Fee Related
- 2003-08-28 CA CA002496523A patent/CA2496523A1/en not_active Abandoned
- 2003-08-28 WO PCT/JP2003/010923 patent/WO2004020633A1/ja active Application Filing
- 2003-08-28 AU AU2003261787A patent/AU2003261787B2/en not_active Ceased
- 2003-08-28 EP EP03791369A patent/EP1536012A4/en not_active Withdrawn
- 2003-08-28 KR KR1020057003095A patent/KR20050058486A/ko not_active Application Discontinuation
- 2003-08-28 JP JP2004532751A patent/JP4463104B2/ja not_active Expired - Fee Related
- 2003-08-28 US US10/526,072 patent/US7482436B2/en not_active Expired - Fee Related
Non-Patent Citations (14)
Title |
---|
"Dictionary of Immunology", 1993, pages: 49 |
D. MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597 |
GEJIMA,R ET AL: "Human single-chain Fv (scFv) antibody specific to human IL-6 with the inhibitory activity on IL-6-signaling.", HUMAN ANTIBODIES, vol. 11, no. 4, 2002, pages 121 - 129, XP002974190 * |
HIRANO T. ET AL., RIC. CLIN. LAB., vol. 19, no. 1, pages 1 - 10 |
KREBS,B ET AL.: "Recombinant Human Single Chain Fv Antibodies Recognizing Human Interleukin-6.", J. BIOL. CHEM., vol. 273, no. 5, 1998, pages 2858 - 2865, XP002921461 * |
MARKS,J.D ET AL.: "By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage.", J. MOL. BIOL., vol. 222, no. 3, 1991, pages 581 - 597, XP000670314 * |
MCCAFFERTY, J. ET AL.: "Antibody Engineering - A Practical Approach", 1996, IRL PRESS |
MONIER S. ET AL., CLIN. EXP. RHEUMATOL., vol. 12, no. 6, November 1994 (1994-11-01), pages 595 - 602 |
MONTERO-JULIAN F.A. ET AL., BLOOD, vol. 85, no. 4, 15 February 1995 (1995-02-15), pages 917 - 24 |
SATO K. ET AL., HUM. ANTIBODIES HYBRIDOMAS, vol. 7, no. 4, 1996, pages 175 - 83 |
See also references of EP1536012A4 * |
VREUGDENHIL G. ET AL., RHEUMATOL. INT., vol. 10, no. 3, 1990, pages 127 - 30 |
WENDLING D. ET AL., J. RHEUMATOL., vol. 20, no. 2, February 1993 (1993-02-01), pages 259 - 62 |
WIJDENES,J ET AL.: "Human recombinant dimeric il-6 binds to its receptor as detected by anti-il-6 monoclonal antibodies.", MOLECULAR IMMUNOLOGY, vol. 28, no. 11, 1991, pages 1183 - 1192, XP002974189 * |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8623362B2 (en) | 2005-04-29 | 2014-01-07 | Janssen Biotech, Inc. | Anti-IL-6 antibodies |
JP2011201888A (ja) * | 2005-04-29 | 2011-10-13 | Centocor Inc | 抗−il−6抗体、組成物、方法および使用 |
US11180549B2 (en) | 2005-04-29 | 2021-11-23 | Janssen Biotech, Inc. | Methods of suppressing rheumatoid arthritis using an anti-IL-6 antibody |
US9631016B2 (en) | 2005-04-29 | 2017-04-25 | Janssen Biotech, Inc. | Pen-injector device containing anti-IL-6 antibodies |
CN102924596A (zh) * | 2005-04-29 | 2013-02-13 | 詹森生物科技公司 | 抗il-6抗体、组合物、方法及应用 |
US9340613B2 (en) | 2005-04-29 | 2016-05-17 | Janssen Biotech, Inc. | Anti-IL-6 antibodies, compositions, methods and uses |
JP2009518023A (ja) * | 2005-12-09 | 2009-05-07 | ユセベ ファルマ ソシエテ アノニム | ヒトil−6に対して特異性を有する抗体分子 |
JP2009545319A (ja) * | 2006-08-03 | 2009-12-24 | バクシネックス,インコーポレーテッド | 抗il−6モノクローナル抗体およびその使用 |
US7919095B2 (en) | 2006-08-03 | 2011-04-05 | Vaccinex, Inc. | Anti-IL-6 monoclonal antibodies |
US8153128B2 (en) | 2006-11-30 | 2012-04-10 | Medimmune Limited | Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor |
US9005620B2 (en) | 2006-11-30 | 2015-04-14 | Medimmune Limited | Compounds |
EP2628751A2 (en) | 2006-11-30 | 2013-08-21 | AstraZeneca AB | Binding members for interleukin-6 and use thereof |
US8198414B2 (en) | 2006-11-30 | 2012-06-12 | Medimmune Limited | Anti-human IL-6 antibodies |
JP2012508762A (ja) * | 2008-11-13 | 2012-04-12 | フェムタ ファーマシューティカルズ インコーポレイテッド | ヒト化抗il−6抗体 |
US11203636B2 (en) | 2017-02-01 | 2021-12-21 | Yale University | Treatment of existing left ventricular heart failure |
US11384143B2 (en) | 2018-01-05 | 2022-07-12 | Novo Nordisk A/S | Methods for treating IL-6 mediated inflammation without immunosuppression |
WO2020223565A1 (en) | 2019-05-01 | 2020-11-05 | Corvidia Therapeutics, Inc. | Anti-il-6 antibody formulation |
Also Published As
Publication number | Publication date |
---|---|
CN1678744B (zh) | 2010-05-26 |
AU2003261787A1 (en) | 2004-03-19 |
EP1536012A4 (en) | 2006-03-08 |
JP4463104B2 (ja) | 2010-05-12 |
US20060240012A1 (en) | 2006-10-26 |
CN1678744A (zh) | 2005-10-05 |
KR20050058486A (ko) | 2005-06-16 |
US7482436B2 (en) | 2009-01-27 |
EP1536012A1 (en) | 2005-06-01 |
CA2496523A1 (en) | 2004-03-11 |
AU2003261787B2 (en) | 2008-11-06 |
JPWO2004020633A1 (ja) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4463104B2 (ja) | ヒト抗ヒトインターロイキン−6抗体及び該抗体フラグメント | |
JP5150516B2 (ja) | 抗体剤ヒトil−22およびその使用 | |
RU2663721C1 (ru) | Моноклональные антитела к человеческому il-17 и их применение | |
JP4914209B2 (ja) | ヒトil−21受容体に対する抗体および該抗体の使用 | |
JP4426449B2 (ja) | ヒト抗ヒトmcp−1抗体及び該抗体フラグメント | |
EP0364778B1 (en) | Antibody against interleukin-1beta | |
AU2004252169A1 (en) | Antibodies against interleukin-22 and uses therefor | |
CA2642570A1 (en) | Methods of using antibodies against human il-22 | |
CN112638946A (zh) | 抗il1rap抗体组合物 | |
AU2002320790B2 (en) | Human type antihuman IgE receptor antibody and antibody fragment | |
Yuan et al. | Construction of human nonimmune library and selection of scFvs against IL-33 | |
KR101525919B1 (ko) | 자가면역 질환 예방 및 치료를 위한 tnfr2를 기반으로 하는 이중 항체 | |
Gejima et al. | Human single-chain Fv (scFv) antibody specific to human IL-6 with the inhibitory activity on IL-6-signaling | |
TWI793503B (zh) | 抗IL-1β抗體 | |
CN118019760A (en) | Anti-IL-1-beta antibodies | |
RU2810206C1 (ru) | Il-18-связывающий белок (il-18bp) и антитела при воспалительных заболеваниях | |
CN113817058A (zh) | 一种抗人il-17rc的单克隆抗体及其应用 | |
WO2023044280A1 (en) | Anti-il-1-beta antibodies | |
WO2006046613A1 (ja) | Il-18様ペプチド、その融合ペプチド、製造方法および用途 | |
JPH0681599B2 (ja) | インターロイキン―1βに対する抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004532751 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2496523 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003261787 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057003095 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006240012 Country of ref document: US Ref document number: 10526072 Country of ref document: US Ref document number: 20038203340 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003791369 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003791369 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057003095 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10526072 Country of ref document: US |